A natural experiment in Kenya reveals durable immunosuppressive effects of early childhood malaria: a longitudinal cohort study

Mercy S. Safari[1,2,6], Timothy O. Makori[1,2], Elijah T. Gicheru[1,2], Maureen W. Mburu[1,2], Omar Nyawa[1,2], Faiz Shee[6], James Nyagwange[1], Eunice W. Kagucia[1], Francis Ndungu[1,3], Timothy Chege[,5], James O. Tuju[1#], Charles J. Sande[1,2,3,4*#]

1. Bioscience Department, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
2.Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
3. Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, UK
4. Kenya Medical Research Institute, Centre for Geographic Medicine Research, Coast, Kilifi, Kenya
5. Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 100322 USA
6. Pwani University, Kilifi, Kenya

* Correspondence to:
Charles J. Sande, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya P.O. Box 230 - 80108 (csande@kemri-wellcome.org)

# Contributed equally

Keywords: malaria, antibody immunosuppression, microarray

Abstract

Background:

Chronic malaria exposure has been proposed to modulate immune function, but its long-term effects on antibody-mediated responses to unrelated pathogens remain poorly defined. Whether these effects persist beyond periods of active infection, and how early-life exposure shapes humoral immunity over time, is not well understood.

Methods:

We leveraged a natural experiment in coastal Kenya - where two regions (Junju and Ngerenya) diverged sharply in malaria transmission from around 2004 - to evaluate the long-term immunological consequences of malaria exposure in childhood. Using a protein microarray platform, we measured IgG responses to vaccine and pathogen antigens in 123 children sampled longitudinally over a 15-year period. Active weekly malaria surveillance enabled precise reconstruction of individual exposure histories.

Results:

IgG responses to *Plasmodium falciparum* apical membrane antigen 1 (AMA1) tracked closely with clinical malaria episodes, confirming the ability of the microarray platform to detect biologically meaningful variation in antigen-specific immunity. Despite comparable vaccination histories, children from the high malaria transmission setting (Junju) exhibited persistently lower measles-specific IgG levels than children from the low-transmission setting (Ngerenya), a pattern validated by ELISA. At 10 years of age, Junju children showed significantly reduced antibody levels to a wide range of unrelated pathogens, including *Bordetella pertussis*, CMV, rubella, and measles. Within the Ngerenya cohort, children with documented early-life malaria had broadly lower IgG responses at age 10 compared to malaria-naïve peers, despite identical geography, vaccines, and follow-up duration.

Conclusions:

These findings suggest that malaria exposure during early childhood is linked with durable suppression of antibody responses to unrelated pathogens and vaccines. This effect persists long after infection and may partially explain the overall diminished long-term vaccine effectiveness in malaria-endemic settings.

Introduction

Malaria remains a major cause of childhood morbidity and mortality in sub-Saharan Africa. In 2023, Africa accounted for 95% of global malaria deaths, with over three-quarters occurring in children under five years old[1]. Alongside malaria, children in these settings face high exposure to a wide array of pathogens - including respiratory, enteric, and helminth infections [2], making immune competence critical for survival and long-term health. Despite widespread vaccination efforts, several studies report reduced vaccine efficacy in malaria-endemic regions compared to malaria-naïve populations [3–5]. Although multiple factors may contribute[6], growing evidence suggests that malaria itself can impair host immunity[5,7,8]. Repeated P. falciparum infection has been associated with immunomodulatory changes, including expansion of regulatory T cells [9,10], regulatory B cells[11], and atypical memory B cells with limited effector function[12,13]. These alterations promote host tolerance for persistent parasitaemia, resulting from recurrent exposure in endemic settings, but they also suppress effector immune responses[14], potentially to unrelated antigens, including vaccines. While malaria-induced immunosuppression has been described in both experimental and observational studies[7,8,15,16], its duration and broader impact on the developing immune system remain poorly understood. Most prior work has focused on short-term or antigen-specific outcomes, leaving open the question of whether early-life malaria exposure durably attenuates antibody responses over the long term. Conflicting findings across settings highlight the need for context-specific, and longitudinal data studies[16,17].

Here, we address this gap using two longitudinal cohorts from coastal Kenya with contrasting malaria transmission histories. One region (Junju) has experienced a sustained malaria burden, while the other (Ngerenya) underwent a rapid decline in transmission after 2004[18]. Intensive weekly malaria surveillance was conducted over more than a decade, enabling precise classification of individual exposure histories. We combined these data with serial serological measurements using a high-throughput in-house protein microarray. This design enabled us to investigate whether clinical malaria in early life leaves a lasting immunological imprint that compromises antibody responses to common childhood pathogens and vaccines. Our findings reveal a durable suppression of humoral immunity

88 linked to malaria exposure in early childhood, with implications for vaccine effectiveness,
89 serosurveillance interpretation, and immune recovery in endemic regions.

90 **Materials and Methods**

91 **Study setting and cohort design -** This study was conducted in Kilifi County, a rural region on
92 the northern coast of Kenya, within the catchment area of the Kilifi Health and Demographic
93 Surveillance System (KHDSS), a long-term population-based platform maintained by the
94 KEMRI-Wellcome Trust Research Programme[19]. Serum samples were obtained
95 retrospectively from two well-characterized paediatric cohorts - Ngerenya and Junju -
96 enrolled between 1998 and 2017 as part of annual malaria cross-sectional surveys[20].
97 Ngerenya and Junju were selected for their contrasting malaria transmission intensities;
98 Ngerenya experienced a sharp decline in malaria transmission beginning in the early
99 2000s[18], whereas Junju maintained moderate malaria endemicity throughout the study
100 period, with *P.falciparum* prevalence approximating 30% during the rainy seasons[21]. All
101 children were visited weekly at home for the detection of febrile episodes, and any child
102 with an axillary temperature ≥37.5°C was tested for P. falciparum parasitaemia using a rapid
103 diagnostic test, with confirmation by microscopic examination of Giemsa-stained thick and
104 thin blood smears. A clinical malaria episode was defined as fever in the presence of ≥2,500
105 parasites/µL. In addition to active malaria surveillance, serum samples were collected
106 annually from each child and for future serological analysis. The vaccination status of each
107 child for routine childhood vaccines was assessed using digitized immunization records
108 stored at the KEMRI-Wellcome Trust Research Programme.

109 **Protein microarray antibody profiling -** Antibody responses were measured using an in-
110 house protein microarray platform. Recombinant and whole-virus lysate antigens
111 (Supplementary table 1) were reconstituted in a glycerol-based buffer containing 1% Triton
112 X-100 and printed in quadruplicate onto epoxy-coated glass slides using a non-contact
113 microarrayer (Marathon Argus, Arrayjet, Scotland). Slides were fitted into hybridization
114 cassettes, washed with PBST (0.05% Tween-20 in PBS), and blocked for 1 hour at 37°C using
115 PBST containing 5% BSA. Serum samples were diluted 1:30 in PBST with 5% BSA and
116 incubated on the slides for 3 hours at room temperature. Slides were washed and probed
117 with secondary antibodies: goat anti-human IgG conjugated to Alexa Fluor 647

118 (SouthernBiotech, cat. no. 2040-03) and goat anti-human IgA conjugated to Alexa Fluor 555
119 (SouthernBiotech, cat. no. 2050-32), each incubated for 1.5 hours at 25°C. Slides were
120 rinsed, disassembled, and scanned using a GenePix 4300A scanner (635 nm at PMT 600, 532
121 nm at PMT 700). Mean fluorescence intensities (MFIs) were extracted from duplicate mini-
122 arrays per slide and averaged across four replicate spots per antigen. Data processing and
123 quality control of microarray data were performed in R (version 4.4.2).

124 **Enzyme-linked immunosorbent assay (ELISA) -** Measles-specific IgG was quantified using a
125 conventional direct ELISA. Plates were coated overnight at 4°C with 2.30 µg/mL measles
126 antigen diluted in PBS. After blocking with 5% skimmed milk for 1 hour at 37°C, serum
127 samples (1:100 dilution) were added and incubated for 1.5 hours at 37°C. Plates were
128 washed with PBST and incubated with HRP-conjugated secondary antibody (1:100 dilution)
129 for 1 hour. Following additional washes, 100 µL of OPD substrate solution (30 mg OPD in 30
130 mL PBS with 30 µL H_2O_2) was added and incubated in the dark for 10 minutes. Reactions
131 were stopped with 50 µL of 2.5 M sulfuric acid, and absorbance was measured at 490 nm.

132 **Statistical analysis -** All statistical analyses were performed using R (version 4.4.2). Antibody
133 responses between cohorts were compared using the Wilcoxon rank-sum test. P-values
134 <0.05 were considered statistically significant. Data were anonymized and delinked from all
135 personally identifiable information.

136 **Ethics statement -** The study was approved by the Scientific and Ethics Review Unit (SERU)
137 of the Kenya Medical Research Institute. All procedures were conducted in accordance with
138 the principles of Good Clinical Laboratory Practice (GCLP).

139 **Results**

140 **A natural experiment in coastal Kenya reveals sharply divergent malaria exposure**
141 **trajectories in early childhood -** Between 1998 and 2017, two rural communities in coastal
142 Kenya - Junju and Ngerenya - underwent markedly different transitions in malaria
143 transmission. Both regions experienced a high malaria burden in the 1990s and early 2000s.
144 However, beginning in 2004, transmission in Ngerenya declined sharply and remained near
145 zero for more than a decade, while Junju continued to experience sustained endemicity well
146 into the mid-2010s. To quantify the scale and timing of this transition, we analyzed

147 surveillance data collected from August 1998 to April 2017. A total of 1,243 children were
148 followed in Ngerenya and 659 in Junju. In Ngerenya, the proportion of febrile surveillance
149 visits with confirmed P. falciparum parasitaemia declined from 22.4% before 2004 (1,378 of
150 6,148 visits) to just 1.1% after 2004 (48 of 4,389 visits). In contrast, Junju children continued
151 to experience high rates of febrile malaria, with 17% of visits testing positive between 2007
152 and 2017 (869 of 5,130 visits) - **Fig. 1**.
153
154 To assess whether the protein microarray platform accurately captured longitudinal P.
155 falciparum-specific immune responses, we examined IgG levels against the plasmodium
156 apical membrane antigen 1 (AMA1) in individual children with known malaria exposure
157 histories. Among children with multiple confirmed episodes of febrile malaria detected via
158 weekly active surveillance, AMA1-specific IgG levels increased sharply over time, tracking
159 closely with the timing of clinical infections (example shown in **Fig. 2a**), while children from
160 Ngerenya who remained malaria-free throughout follow-up exhibited consistently low IgG
161 levels against AMA1 over more than a decade of surveillance (example shown in **Fig. 2b**).
162 These patterns mirrored expected immunological trajectories of repeated exposure versus
163 non-exposure, confirming that the microarray platform is capable of detecting meaningful
164 variation in P. falciparum-specific humoral responses. We then extended this analysis to
165 assess longitudinal IgG responses to AMA1 in a subset of 123 children drawn from the two
166 surveillance cohorts. These children contributed a total of 1,194 serum samples, with a
167 mean of 10 samples per child, collected between 2002 and 2017 (**Supplementary Fig. 1**).
168 This subset was selected on the basis of the relative completeness of their longitudinal
169 follow-up serum sampling and included 58 children from Junju (505 samples) and 65 from
170 Ngerenya (689 samples). AMA1-specific IgG levels diverged sharply between cohorts early in
171 life and remained distinct throughout follow-up. In Ngerenya, levels declined rapidly after
172 2003, stabilizing at lower levels by mid-childhood. In contrast, Junju children maintained
173 elevated levels across all time points (**Fig. 2c**).
174
175 **Malaria-exposed children exhibit lower antibody levels to non-malarial antigens -** To
176 examine the impact of differential malaria endemicity on the antibody response to non-
177 malarial antigens, we first compared IgG responses to the measles virus among Junju and
178 Ngerenya children. We started by validating the ability of the in-house protein microarray

179 platform to detect biologically meaningful measles-specific IgG responses by examining
180 longitudinal measles levels in individual children with known vaccination histories. Among
181 children with a documented history of receiving all three recommended doses of measles
182 vaccine, we observed a sharp rise in IgG levels following immunization, followed by
183 sustained levels into later childhood (example shown in **Fig. 3a**). In contrast, unvaccinated
184 children exhibited consistently low IgG trajectories across all time points (example shown in
185 **Fig. 3b**). These patterns were reproducible across the cohort and recapitulated expected
186 vaccine-induced versus naïve antibody dynamics, supporting the use of this platform for
187 population-level serological inference. Using this platform, we then compared IgG responses
188 to measles virus among children from Junju and Ngerenya. This analysis was restricted only
189 to children with a documented record of measles vaccination. Despite matched vaccination
190 histories, children from Junju - where malaria transmission remained high - consistently
191 exhibited lower measles-specific IgG titers than children from Ngerenya, where malaria
192 transmission had declined. This difference was evident from the earliest timepoints and
193 persisted throughout childhood. Annual antibody measurements showed that mean
194 measles-specific IgG levels were higher in Ngerenya than in Junju in every sampling year (**Fig.**
195 **3c**). To validate these findings, we measured measles-specific IgG levels by ELISA in a subset
196 of 3-year-old children who had completed measles vaccination at least one year prior. In this
197 assay, Junju children again displayed significantly lower IgG levels than their Ngerenya
198 counterparts (**Fig. 3d**).
199
200 **Early-life malaria exposure is associated with long-term suppression of antibody responses**
201 To assess whether the attenuation of antibody responses extended beyond measles, we
202 compared IgG levels to a broader panel of antigens at 10 years of age. This analysis included
203 vaccine-preventable pathogens (*Bordetella pertussis*, H1N1 influenza virus, rubella virus, and
204 measles virus) and common childhood infections (cytomegalovirus (CMV), Epstein-Barr virus
205 (EBV), herpes simplex virus 1 (HSV-1), coxsackievirus B1). Children from Junju exhibited
206 significantly lower IgG levels for most antigens compared to their Ngerenya counterparts
207 (**Fig. 4**). This pattern was observed for both viral and bacterial pathogens and was
208 particularly marked for coxsackievirus, EBV, HSV-1, and measles. Antibody levels against P.
209 falciparum AMA1 remained elevated in Junju. Antibody levels to the 2009 pandemic strain

210 of H1N1 were the least differentiated between cohorts, although Ngerenya children still
211 exhibited significantly higher levels than Junju participants (**Fig. 4**).
212
213 To determine whether the attenuation of antibody responses could still be attributed to
214 early-life malaria exposure independent of geographic or environmental differences, we
215 conducted a stratified analysis within the Ngerenya cohort, which experienced a sharp
216 decline in malaria transmission beginning in 2004. Due to stochastic differences in malaria
217 infection around the time of this inflection, children in Ngerenya had different malaria
218 exposure histories despite living in the same area. At the 10-year-of-age time point, sera
219 were available for 62 out of the 65 children that were originally selected in the Ngerenya
220 cohort subset for serological analysis. Of these, 20 experienced one or more episodes of
221 febrile malaria during early childhood prior to the decline in malaria transmission, while 42
222 remained entirely malaria-free throughout follow-up (**Fig. 5a**). At 10 years of age, Ngerenya
223 children who had experienced early-life malaria exhibited significantly lower IgG levels to a
224 wide range of antigens compared to their malaria-naïve peers (**Fig. 5b**). These included
225 responses to Coxsackievirus B1, CMV, H1N1 influenza, HSV-1 and rubella. Differences in
226 antibody level to *B. pertussis* and EBV did not reach statistical significance.
227
228 **Discussion**
229 This study demonstrates that early-life exposure to malaria is associated with broad and
230 durable impairments in antibody-mediated immunity to unrelated pathogens and vaccines.
231 By leveraging a natural experiment in coastal Kenya - where malaria transmission diverged
232 sharply between adjacent communities during the early 2000s - we were able to disentangle
233 the immunological effects of malaria exposure from confounding geographic and temporal
234 factors. Our findings reveal that children exposed to malaria in early childhood not only
235 generate lower antibody titres to non-malarial antigens but maintain these attenuated
236 responses well into adolescence, long after malaria transmission has ceased. The
237 attenuating effect of malaria on antibody responses has long been suspected [15] but difficult
238 to quantify. Prior studies have shown reduced vaccine efficacy in malaria-endemic settings
239 [3,16], and experimental models have implicated regulatory T cells, atypical memory B cells,
240 and B cell exhaustion as potential mediators of malaria-induced immune suppression[9,12,13,22].
241 However, most human studies to date have focused on short-term immune responses or

242 outcomes in the setting of concurrent parasitaemia. Our data extend this work by
243 demonstrating that transient exposure to malaria in early childhood is sufficient to imprint
244 long-lasting changes on the humoral immune repertoire.
245
246 The strength of this study lies in its integration of long-term active malaria surveillance with
247 serial antibody profiling. Children were visited weekly for febrile illness surveillance, allowing
248 for precise documentation of clinical malaria episodes. In parallel, our use of a validated
249 protein microarray platform enabled us to track IgG responses to a wide panel of pathogen
250 and vaccine antigens at multiple timepoints. We first confirmed that the microarray platform
251 captured biologically relevant responses by comparing antibody trajectories in individual
252 children with known measles vaccination and malaria exposure histories. The platform
253 reliably detected both vaccine-induced and infection-associated rises in IgG, providing
254 confidence in the longitudinal patterns observed. We found that children from Junju, a
255 region of persistent transmission, had significantly lower antibody levels to multiple
256 pathogens compared to children from Ngerenya, where malaria transmission declined in the
257 mid-2000s. These differences were most pronounced for antigens such as measles virus,
258 *Bordetella pertussis*, CMV, rubella virus, and HSV-1. Importantly, all children had comparable
259 vaccination histories and were followed through the same longitudinal infrastructure,
260 minimizing the likelihood of differential healthcare access or vaccine uptake.
261
262 To test whether early-life malaria exposure specifically contributed to long-term immune
263 suppression, we examined antibody responses within the Ngerenya cohort. Because the
264 transmission decline occurred rapidly, children born just before and after the inflection point
265 experienced markedly different levels of malaria exposure while living in the same
266 geographic area. Among children followed longitudinally, those with even limited early-life
267 exposure to malaria had significantly lower antibody titers at 10 years of age than their
268 malaria-naïve peers. This within-cohort contrast strongly implicates early-life infection as the
269 critical window for immune programming. Taken together, these findings support a model in
270 which malaria exposure during critical developmental windows modulates long-term
271 maintenance of immune memory. This may occur through direct effects on B cell
272 maturation, altered antigen presentation[23], or long-lived changes in lymphoid
273 microenvironments[24–26]. While the mechanistic basis of this phenomenon remains to be fully

274 explained, the consistency of the attenuation on multiple antigens and timepoints suggests a
275 generalizable effect rather than antigen-specific phenomenon.
276
277 This work has important implications for vaccine policy and infection risk in malaria-endemic
278 regions. Reduced antibody titres to vaccine-preventable diseases may translate into
279 diminished long-term protection, even when vaccine coverage is high. Our findings raise the
280 possibility that children in high-transmission settings may require different immunization
281 strategies, such as delayed dosing and boosting, to improve vaccine-induced immunity.
282 Moreover, as malaria control efforts continue to shift disease epidemiology, these data
283 highlight the value of longitudinal serological surveillance for understanding the broader
284 immunological legacy of malaria exposure. Our study has several limitations. Although the
285 microarray platform was validated internally and against ELISA, quantitative comparisons
286 across platforms are inherently constrained. Additionally, while the sample size for antibody
287 profiling was modest, the inclusion of dense longitudinal sampling and detailed clinical
288 surveillance adds depth to the dataset. Finally, we cannot fully exclude the influence of other
289 infections or environmental exposures that may have differed subtly between subgroups,
290 although the within-Ngerenya analysis provides strong evidence for malaria as a primary
291 driver of long-term immune attenuation.
292
293 In summary, our findings reveal that early-life malaria exposure is associated with long-term
294 suppression of antibody responses to unrelated pathogens and vaccines. This effect is
295 detectable many years after infection, and appears to persist even in the absence of ongoing
296 transmission. As global malaria control efforts continue, understanding the immunological
297 legacy of childhood malaria may be critical for improving vaccination strategies and
298 mitigating susceptibility to other infections.

Figures



Figure 1

302



303

304 Figure 2

305

306



307

308 Figure 3

309



310

311 Figure 4

312



314 Figure 5

Figure captions

Figure 1

Divergent malaria exposure histories in coastal Kenya - Monthly malaria case counts from active surveillance in two adjacent regions of Kilifi County, Kenya, between 1998 and 2017. Junju (red) maintained sustained malaria transmission throughout the study period, while Ngerenya (blue) experienced a rapid collapse in transmission beginning in 2004. Points represent total cases per month; lines show LOESS-smoothed trends.

Figure 2

AMA1-specific IgG trajectories mirror individual and regional malaria exposure - (A–B) Longitudinal AMA1 IgG levels in individual children measured by protein microarray. Vertical red lines denote confirmed febrile malaria episodes. Panel A shows a Junju child with multiple documented infections; Panel B shows a Ngerenya child who remained malaria-free throughout follow-up. Each blue spot is a single antibody measurement. Each time point was measured in quadruplicate **(C)** Mean AMA1-specific IgG levels with 95% confidence intervals for all children in the microarray subset plotted by year of sampling. Junju children showed persistently elevated antibodies, while AMA1 antibody levels in Ngerenya declined sharply after 2004.

Figure 3

Malaria exposure is associated with reduced measles-specific antibody levels. Example plots of temporal changes in measles-specific antibody in vaccinated and unvaccinated children are shown **(A)** Longitudinal IgG levels in an individual child measured by microarray. The dashed vertical red line indicates the timing of the last dose of the routine measles vaccine. **(B)** Shows a similar temporal trend for a child with no history of measles vaccination. **(C)** Longitudinal IgG responses to measles virus by cohort, measured by protein microarray in vaccinated children. Junju children exhibited consistently lower levels of measles-specific antibody than Ngerenya counterparts. The circles indicate means, and the whiskers denote 95% confidence intervals. **(C)** Measles-specific IgG levels in 3-year-old children from Junju and Ngerenya, measured by ELISA in children with a documented history of measles vaccination. Each dot represents an individual participant.

Figure 4

Broad suppression of antibody responses to diverse pathogens in malaria-exposed children - cross-sectional IgG titres at 10 years of age for a panel of pathogen and vaccine antigens, measured by protein microarray. Each dot represents an individual child; boxes indicate interquartile ranges, with the midline denoting the median. Junju children show significantly lower antibody levels across most antigens compared to Ngerenya children, including *Bordetella pertussis*, H1N1 influenza virus, rubella virus, measles virus, cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus 1 (HSV-1), and coxsackievirus B1.

Figure 5

Early-life malaria exposure predicts long-term suppression of antibody responses within the same geographic region - (A) Active malaria surveillance records for children in the Ngerenya cohort. Each row represents an individual child, and each column represents a surveillance timepoint. Dark red boxes indicate one or more confirmed febrile malaria episodes; light grey boxes indicate surveillance visits without malaria detection. Children are grouped by early-life exposure status (top: malaria-naïve; bottom: previously exposed). **(B)** IgG levels at 10 years of age among Ngerenya children, stratified by early-life malaria exposure. Children with ≥1 confirmed febrile malaria episode during early childhood (n = 20) show significantly lower titres to multiple unrelated pathogens compared to malaria-naïve peers (n = 42). All children lived in the same geographic area and received identical vaccines and follow-up. The black dots are means and error bars are 95% confidence intervals.

Supplementary Figure 1

A summary of the sampling frame for the study cohorts (Junju and Ngerenya). Each vertical line represents the longitudinal time series for a single individual, and each dot represents a timepoint where a serum sample was collected.

Supplementary Table 1

378 Summary of pathogens, strains or subtypes, and corresponding antigens included in the
379 immunoassay panel.

Data and Code Availability

The datasets and R scripts used for the analysis in this study are available from the corresponding author upon reasonable request. Due to local laws and regulations, individual-level data from the Kilifi Health and Demographic Surveillance System (KHDSS), cannot be made publicly available. All data processing and visualization were performed using open-source R packages; package versions and analysis pipelines are available upon request.

Funding statement

This study was supported by fellowship funding to C.J.S. from the Wellcome Trust (WT105882MA). The funder played no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript. M.S.S was funded in whole by Science for Africa Foundation to the Developing Excellence in Leadership, Training, and Science in Africa (DELTAS Africa) program [DEL-22-012] with support from Wellcome Trust and the UK Foreign, Commonwealth & Development Office and is part of the EDCPT2 programme supported by the European Union. For purposes of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.

401 **References**

402 1 World Health Organization. World malaria report 2024. Geneva, 2024
403 https://www.who.int/publications/i/item/9789240086173.

404 2 Reiner RC, LBD Triple Burden Collaborators, Welgan CA, *et al.* The overlapping burden of
405 the three leading causes of disability and death in sub-Saharan African children. *Nat*
406 *Commun* 2022; **13**: 7457.

407 3 Bejon P, Mwacharo J, Kai O, *et al.* The induction and persistence of T cell IFN-gamma
408 responses after vaccination or natural exposure is suppressed by Plasmodium falciparum.
409 *J Immunol* 2007; **179**: 4193–201.

410 4 RTS,S Clinical Trials Partnership, Agnandji ST, Lell B, *et al.* A phase 3 trial of RTS,S/AS01
411 malaria vaccine in African infants. *N Engl J Med* 2012; **367**: 2284–95.

412 5 Cunnington AJ, Riley EM. Suppression of vaccine responses by malaria: insignificant or
413 overlooked? *Expert Rev Vaccines* 2010; **9**: 409–29.

414 6 P Z, N C. Factors That Influence the Immune Response to Vaccination. *PubMed* 2019.
415 https://pubmed.ncbi.nlm.nih.gov/30867162/ (accessed April 25, 2025).

416 7 Bediako Y, Adams R, Reid AJ, *et al.* Repeated clinical malaria episodes are associated with
417 modification of the immune system in children. *BMC Med* 2019; **17**: 60.

418 8 Calle CL, Mordmüller B, Singh A. Immunosuppression in Malaria: Do Plasmodium
419 falciparum Parasites Hijack the Host? *Pathogens* 2021; **10**: 1277.

420 9 Kurup SP, Obeng-Adjei N, Anthony SM, *et al.* Regulatory T cells impede acute and long-
421 term immunity to blood-stage malaria through CTLA-4. *Nat Med* 2017; **23**: 1220–5.

422 10 Walther M, Tongren JE, Andrews L, *et al.* Upregulation of TGF-beta, FOXP3, and
423 CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human
424 malaria infection. *Immunity* 2005; **23**: 287–96.

425 11 Han X, Yang J, Zhang Y, *et al.* Potential Role for Regulatory B Cells as a Major Source of
426 Interleukin-10 in Spleen from Plasmodium chabaudi-Infected Mice. *Infect Immun* 2018;
427 **86**: e00016-18.

428 12 Illingworth J, Butler NS, Roetynck S, *et al.* Chronic exposure to Plasmodium falciparum is
429 associated with phenotypic evidence of B and T cell exhaustion. *J Immunol* 2013; **190**:
430 1038–47.

431 13 Weiss GE, Crompton PD, Li S, *et al.* Atypical Memory B Cells Are Greatly Expanded in
432 Individuals Living in a Malaria-Endemic Area. *The Journal of Immunology* 2009; **183**:
433 2176–82.

434 14 Portugal S, Moebius J, Skinner J, *et al.* Exposure-dependent control of malaria-induced
435 inflammation in children. *PLoS Pathog* 2014; **10**: e1004079.

436 15 Greenwood BM, Bradley-Moore AM, Bryceson AD, Palit A. Immunosuppression in
437 children with malaria. *Lancet* 1972; **1**: 169–72.

438 16 Zirimenya L, Natukunda A, Nassuuna J, *et al.* The Effect of Malaria on Responses to
439 Unrelated Vaccines in Animals and Humans: A Systematic Review and Meta-Analysis.
440 *Parasite Immunology* 2024; **46**: e13067.

441 17 Crawley J, Sismanidis C, Goodman T, Milligan P. Effect of intermittent preventive
442 treatment for malaria during infancy on serological responses to measles and other
443 vaccines used in the Expanded Programme on Immunization: results from five
444 randomised controlled trials. *The Lancet* 2012; **380**: 1001–10.

445 18 O'Meara WP, Mwangi TW, Williams TN, McKenzie FE, Snow RW, Marsh K. Relationship
446 between exposure, clinical malaria, and age in an area of changing transmission intensity.
447 *Am J Trop Med Hyg* 2008; **79**: 185–91.

448 19 Scott JAG, Bauni E, Moisi JC, *et al.* Profile: The Kilifi Health and Demographic Surveillance
449 System (KHDSS). *Int J Epidemiol* 2012; **41**: 650–7.

450 20 Mwangi TW, Ross A, Snow RW, Marsh K. Case definitions of clinical malaria under
451 different transmission conditions in Kilifi District, Kenya. *J Infect Dis* 2005; **191**: 1932–9.

452 21 Bejon P, Williams TN, Liljander A, *et al.* Stable and unstable malaria hotspots in
453 longitudinal cohort studies in Kenya. *PLoS Med* 2010; **7**: e1000304.

454 22 Portugal S, Obeng-Adjei N, Moir S, Crompton PD, Pierce SK. Atypical memory B cells in
455 human chronic infectious diseases: An interim report. *Cell Immunol* 2017; **321**: 18–25.

456 23 Yap XZ, Lundie RJ, Beeson JG, O'Keeffe M. Dendritic Cell Responses and Function in
457 Malaria. *Front Immunol* 2019; **10**: 357.

458 24 Cadman ET, Abdallah AY, Voisine C, *et al.* Alterations of splenic architecture in malaria are
459 induced independently of Toll-like receptors 2, 4, and 9 or MyD88 and may affect
460 antibody affinity. *Infect Immun* 2008; **76**: 3924–31.

461 25 Obeng-Adjei N, Portugal S, Holla P, *et al.* Malaria-induced interferon-γ drives the
462 expansion of Tbethi atypical memory B cells. *PLoS Pathog* 2017; **13**: e1006576.

463 26 Weiss GE, Traore B, Kayentao K, *et al.* The Plasmodium falciparum-specific human
464 memory B cell compartment expands gradually with repeated malaria infections. *PLoS*
465 *Pathog* 2010; **6**: e1000912.

466

467 **Supplementary Materials**

468



469

470 Supplementary figure 1

471

472

473

Pathogen	Strain/subtype	Antigen
Measles virus	Edmonston	Whole virus antigen
Coxsackie B virus	B1	VP1
Cytomegalovirus	TB40E	PP150
Epstein-Barr virus	Type 1	Nuclear antigen 1
Herpes simplex virus	Type 1	Extract
H1N1 Influenza A	A/California/07/2009	Haemagluttinin
Plasmodium falciparum	3D7	AMA-1
Rubella virus	HPV-77	Whole virus antigen

474

475

476 Supplementary table 1